Should the drug industry work with key opinion leaders? No
- 19 June 2008
- Vol. 336 (7658), 1405
- https://doi.org/10.1136/bmj.39541.731493.59
Abstract
Industry commonly works with experts to put across its message. Charlie Buckwell (doi: 10.1136/bmj.39541.702870.59) believes that such interaction is essential for medical advancement, but Giovanni Fava argues that it risks scientific integrity The proliferating connections between doctors and the drug industry have brought the credibility of clinical medicine to an unprecedented crisis. Corporate actions that have placed profit over public health have become regular news. High profile examples include the misrepresentation of research on rofecoxib and on the use of selective serotonin reuptake inhibitors in children. Recently, two respected scientists who work for a drug company wrote that the problem of conflict of interest “could well erode the credibility of the entire enterprise of academic medicine, if not properly and promptly addressed.”1 2 The game is clear: to get as close as possible to universal prescribing of a drug by manipulating evidence and withholding data. A recent paper illustrates how selective publication of trials of antidepressants exaggerated their efficacy.3 Thirty seven of …This publication has 7 references indexed in Scilit:
- Selective Publication of Antidepressant Trials and Its Influence on Apparent EfficacyThe New England Journal of Medicine, 2008
- Ladas and MOTsBMJ, 2008
- A National Survey of Physician–Industry RelationshipsThe New England Journal of Medicine, 2007
- Financial conflicts of interest in psychiatry.2007
- Conflicts of interest and the credibility of psychiatric research.2007
- Conflict, what conflict?Western Journal of Medicine, 2000
- Scientific Journals and Their Authors’ Financial Interests: A Pilot StudyPsychotherapy and Psychosomatics, 1998